Loading
A phase 1 trial of NRM-823 run by Normunity AccelCo, Inc., now recruiting.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors is a phase 1 interventional study registered as NCT07182149 by Normunity AccelCo, Inc., with 150 participants planned, started 2025-10-30. Conditions recorded: HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer and Triple Negative Breast Cancer (TNBC). Interventions recorded: NRM-823.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma, Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Cervical cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/